Literature DB >> 21562766

The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus.

Abdolrahim Nikzamir1, Alireza Esteghamati, Amir Abbas Hammedian, Touraj Mahmoudi.   

Abstract

Observations on the association between the vascular endothelial growth factor (VEGF) gene polymorphism and nephropathy have been inconsistent, which might be due to ethnic and geographical variations. Furthermore, the relationship between +405 G/C polymorphism and albuminuria in the diabetic population has not been sufficiently studied. The aim of this study was to evaluate for the first time the possible association between +405 G/C polymorphism and albuminuria in an population from Tehran of Iran. A total of 255 consecutive patients with type 2 diabetes and microalbuminuria (Group A) and 235 patients with type 2 diabetes and normoalbuminuria (Group B) were included. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) were used to detect the VEGF alleles. In univariate analysis, the groups were statistically similar in all variables except for HbA1c (8.53 ± 1.7 in Group A vs. 8.2 ± 1.73 in Group B; P = 0.034), 24-h urinary albumin (201.33 ± 84.8 in Group A vs. 22.88 ± 3.5 in Group B; P < 0.001), and the frequency of GG genotype (31% in Group A vs. 18.7% in Group B; P = 0.006). The GG genotype was the independent predictor of albuminuria [P = 0.014, OR = 1.771, 95% confidence interval (CI) = 1.124-2.790]. Our study showed that the G allele was not associated with albuminuria, but the GG genotype in the VEGF gene is independently associated with development of nephropathy in the our diabetic population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562766     DOI: 10.1007/s11033-011-0812-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  45 in total

1.  VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5.

Authors:  Angela M Summers; Beatrice M Coupes; Mary Frances Brennan; Shirley A Ralph; Colin D Short; Paul E C Brenchley
Journal:  Nephrol Dial Transplant       Date:  2005-07-26       Impact factor: 5.992

Review 2.  Pathogenesis of diabetic nephropathy.

Authors:  A E Raptis; G Viberti
Journal:  Exp Clin Endocrinol Diabetes       Date:  2001       Impact factor: 2.949

Review 3.  Endothelial dysfunction in diabetes.

Authors:  A S De Vriese; T J Verbeuren; J Van de Voorde; N H Lameire; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

4.  Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients.

Authors:  Monika Buraczynska; Piotr Ksiazek; Iwona Baranowicz-Gaszczyk; Lucyna Jozwiak
Journal:  Nephrol Dial Transplant       Date:  2006-11-22       Impact factor: 5.992

Review 5.  Vascular endothelial growth factors and angiogenesis in eye disease.

Authors:  A N Witmer; G F J M Vrensen; C J F Van Noorden; R O Schlingemann
Journal:  Prog Retin Eye Res       Date:  2003-01       Impact factor: 21.198

6.  A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.

Authors:  Takuya Awata; Kiyoaki Inoue; Susumu Kurihara; Tomoko Ohkubo; Masaki Watanabe; Kouichi Inukai; Ikuo Inoue; Shigehiro Katayama
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

Review 7.  Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator.

Authors:  Fuad N Ziyadeh
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

8.  Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man.

Authors:  B Hohenstein; B Hausknecht; K Boehmer; R Riess; R A Brekken; C P M Hugo
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

9.  Vascular endothelial growth factor in diabetic nephropathy.

Authors:  Tomas Lenz; Thomas Haak; Joanna Malek; Hermann-Josef Gröne; Helmut Geiger; Jan Gossmann
Journal:  Kidney Blood Press Res       Date:  2003       Impact factor: 2.687

10.  Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases.

Authors:  K Shulman; S Rosen; K Tognazzi; E J Manseau; L F Brown
Journal:  J Am Soc Nephrol       Date:  1996-05       Impact factor: 10.121

View more
  6 in total

1.  Vascular endothelial growth factor (VEGF) +405 C/G polymorphism is associated with essential hypertension in a population from Tehran of Iran.

Authors:  Amir Abbas Hamedian; Alireza Esteghamati; Sina Noshad; Mohammad Mozafari; Hosein Moin-Tavakkoli; Manouchehr Nakhjavani; Touraj Mahmoudi; Mahfam Nikzamir; Reza Safary; Abdolrahim Nikzamir
Journal:  Mol Biol Rep       Date:  2011-12-31       Impact factor: 2.316

2.  Association between the polymorphisms of the vascular endothelial growth factor gene and metabolic syndrome.

Authors:  Young Ree Kim; Seung-Ho Hong
Journal:  Biomed Rep       Date:  2015-02-04

3.  VEGF genetic polymorphisms may contribute to the risk of diabetic nephropathy in patients with diabetes mellitus: a meta-analysis.

Authors:  Li Sun; Quan Yuan; Ning Cao; Wei Guo; Li Yao; Jiang-Min Feng; Jian-Fei Ma; Li-Ning Wang
Journal:  ScientificWorldJournal       Date:  2014-08-11

4.  Meta-Analysis and Bioinformatics Detection of Susceptibility Genes in Diabetic Nephropathy.

Authors:  Maria Tziastoudi; Christos Cholevas; Theoharis C Theoharides; Ioannis Stefanidis
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

5.  Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer.

Authors:  Diana Cornelia Moisuc; Mihai Vasile Marinca; Bogdan Gafton; Teodora Alexa-Stratulat; Mariana Pavel-Tanasa; Petru Cianga
Journal:  Curr Oncol       Date:  2022-05-31       Impact factor: 3.109

Review 6.  Association between Genetic Variants and Diabetes Mellitus in Iranian Populations: A Systematic Review of Observational Studies.

Authors:  Mehrnoosh Khodaeian; Samaneh Enayati; Ozra Tabatabaei-Malazy; Mahsa M Amoli
Journal:  J Diabetes Res       Date:  2015-10-26       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.